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Levels of vascular endothelial growth factor are elevated in patients
with obstructive sleep apnea–hypopnea syndrome
Shigehiko Imagawa, Yuji Yamaguchi, Masato Higuchi, Tomohiro Neichi, Yuichi Hasegawa, Harumi Y. Mukai,
Norio Suzuki, Masayuki Yamamoto, and Toshiro Nagasawa
To better understand how humans adapt
to hypoxia, the levels of hemoglobin (Hb),
serum erythropoietin (Epo), and vascular
endothelial growth factor (VEGF) were
measured in 106 patients with severe
obstructive sleep apnea-hypopnea syn-
drome. The results indicated that tempo-
ral hypoxic stimulation increases Hb. Fur-
thermore, a minor increase in Epo and a
substantial increase in VEGF were found.
Theinductioninpatientswithseveresleep
apnea was greater than that reported in
other types of hypoxia. (Blood. 2001;98:
1255-1257)
© 2001 by TheAmerican Society of Hematology
Introduction
Remarkable progress has been made in understanding the molecu-
lar basis of oxygen sensing and transcriptional regulation of
physiologically relevant genes, including those encoding erythro-
poietin (Epo) and vascular endothelial growth factor (VEGF).1
Induction of these genes confers multiple responses for mainte-
nance of oxygen hemostasis. At the transcriptional level, these
genes are all under the control of hypoxia-inducible factor-1
(HIF-1).2 There is an HIF-1 binding site in the enhancer of the Epo
gene2 and in the promoter of the VEGF gene.3 Both of these genes
are induced by hypoxia in vivo and in vitro by means of a common
oxygen and signaling pathway.1 HIF-1 is a widely expressed
heterodimeric protein composed of HIF-1a and aryl hydrocarbon
nuclear translocator (ARNT) subunits, both of which belong to the
rapidly growing PAS family of basic helix-loop-helix (bHLH)
transcription factors.4 At the messenger RNA (mRNA) level, both
HIF-1 and ARNT genes are constitutively expressed and not
signiﬁcantly up-regulated by hypoxia. Whereas changes in oxygen
tension do not affect ARNT protein abundance, hypoxia markedly
increases the levels of HIF-1a protein.5 The oxygen-dependent
degradation (ODD) of HIF-1a is mediated by an internal 200-
residue ODD domain via the ubiquitin-proteasome pathway.6
Despite these ﬁndings in vitro, very little is known about the steps
underlying the activation of HIF-1 through the oxygen sensor by
hypoxia in humans. Plasma Epo increases exponentially with the
degree of hypoxia in humans.7 High altitude stimulates Epo
production in humans.8 Obstructive sleep apnea is a recognized
cause of sleep-associated hypoxemia.9 Nocturnal oxygenation
correlates with daytime awake arterial oxygen saturation, but it
cannot be accurately predicted from awake measurements of
oxygenation in patients with obstructive sleep apnea or chronic
obstructive pulmonary disease.10 Intermittent nocturnal hypoxia in
patients with obstructive sleep apnea was not accompanied by
elevated serum Epo or erythrocytosis.11 However, the number of
the subjects in this study was small (n 5 26) and did not include
severely affected patients. In the present study, the responses of
VEGF and Epo to temporal hypoxic stimulation were assayed in
patients with severe obstructive sleep apnea-hypopnea syn-
drome (OSAHS).
Study design
We measured the levels of hemoglobin (Hb), serum VEGF, and Epo in
patients with severe OSAHS (n 5 106) and compared them with the levels
in controls (n 5 45). Individuals with anemia (Hb , 12.0 g/dL), renal or
liver disease, and coronary artery disease were excluded. Assays of serum
VEGF and Epo were performed by enzyme-linked immunosorbent assay.
Serum samples were obtained from the patients when they ﬁrst came to the
clinic. The patients, all of whom had severe OSAHS, were divided into 5
groups according to the apnea-hypopnea index (AHI; 30-49, 50-69, 70-89,
90-109, and . 110) and the controls had anAHI of less than 5, as shown in
Table 1.
Results and discussion
With increases in the AHI, PaO2 signiﬁcantly decreased from
89.8% 6 9.4% (in the control group) to 78.2% 6 5.1% (in the
AHI . 110 group) (Figure 1). In contrast to PaO2, Hb signiﬁcantly
increased from 14.5 6 1.4 g/dL (control) to 17.2 6 0.3 g/dL
(AHI . 110 group) (Table 1). Serum VEGF levels signiﬁcantly
(P , .005) increased from 150 6 111 (control) to 755 6 182
pg/mL (AHI . 110 group), 5 times higher than the control level
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mU/mL (Table 1). Compared with the control level, Epo levels in
the AHI 30 to 49, 50 to 69, and 70 to 89 groups were increased to
17, 13, and 16 mU/mL, respectively (P , .025), 1.6 times higher
than the control level (P , .025) (Table 1). However, the levels in
the AHI 90 to 109 and AHI greater than 110 groups were not
increased (P . .05) (Table 1). Furthermore, there were no signiﬁ-
cant relationships between Epo and Hb, between VEGF and Hb, or
between Epo and VEGF (data not shown).
Moore-Gillon and Cameron demonstrated that 2 hours of
hypoxia (12% oxygen) per day leads to a rise in red cell mass in rats
and that there is a dose-response relationship between the duration
of hypoxia and red cell mass.12 Other workers have shown that 1
hour of hypoxia (10% oxygen) per day leads to a rise in hematocrit
in rats.13 However, despite substantial nocturnal hypoxemia in
some patients in the former study, there was no signiﬁcant effect on
serum Epo, and no signiﬁcant change occurred when nocturnal
hypoxemia was corrected by nasal continuous positive airway
pressure.11 Also, no patient had a serum Epo level more than 48
mU/mL, which was the upper limit of the normal range for the
assay system used.11 Thus, intermittent nocturnal hypoxemia in the
patients was not accompanied by signiﬁcantly elevated serum Epo
levels.This ﬁnding conﬂicted with those of Cahan and associates,14
who demonstrated that serum Epo levels in patients with obstruc-
tive sleep apnea were approximately 2-fold higher than those in
normal subjects. Daytime hypoxemia appears to be an important
determinant of serum Epo and red cell mass15 in patients with
chronic lung disease, but nocturnal hypoxemia does not appear to exert
an appreciable independent inﬂuence on erythrocyte production.16
We found an increase in Hb, a minor increase in Epo, and a
substantial increase in VEGF in the patients with OSAHS. The
1.6-fold increase in Epo in our study was compatible with that in a
previous report.14 This result indicates that a small increase in Epo
allows for a corresponding increase in red cell mass. The resultant
enhanced delivery of oxygen to tissues then dampens the hypoxic
signal, thereby shutting off further stimulus for Epo gene transcrip-
tion. This represents the closing of a negative feedback loop.
As to the response of VEGF by hypoxia, Gunga and colleagues
reported reduced VEGF concentrations immediately after an
ultramarathon run at high altitude.17 Asano and coworkers mea-
sured a transient decrease of serum VEGF 10 days after the
beginning of altitude training at 1886 m, followed by an increase,
reaching maximum values on day 19.18 Schobersberger and
associates reported that VEGF in a group of runners was signiﬁ-
cantly elevated after they ran the Swiss Alpine Marathon of Devos
(distance 67 km, altitude difference 2300 m) and further increased
2.4-fold until day 5 after exposure. Epo was also increased after
exercise but reached a maximum 2 hours after the run (2-fold
increase) and decreased thereafter.19 They concluded that the
increase of VEGF was due to both the stimulation of hypoxia and
exercise. Especially after exercise, the tissue damage that occurred
as a result of running increased the levels of cytokines such as
interleukin 6 (IL-6) and tumor necrosis factor-a (TNF-a) which, in
turn, may have stimulated the production of VEGF mRNA.20 It is
possible, though unlikely, that changes in IL-6 and TNF-a in
patients with OSAHS contribute to the observed increase in VEGF
and Epo.
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